Consolidation chemotherapy in advanced epithelial ovarian carcinoma: a prospective randomized controlled trial
- VernacularTitle:晚期卵巢上皮癌的巩固化疗——一项前瞻性随机对照试验
- Author:
Ninghai CHENG
;
Huifang HUANG
;
Linya PAN
- Publication Type:Journal Article
- Keywords:
ovarian neoplasms;
consolidation chemotherapy;
neoplasm recurrence
- From:
Medical Journal of Chinese People's Liberation Army
2001;0(07):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects of consolidation chemotherapy on postponing the relapse in patients with advanced epithelial ovarian carcinoma. Methods 44 patients with advanced epithelial ovarian carcinoma treated in our hospital from March 2000 to April 2004 were enrolled. Clinical complete remission was achieved after standard treatments in all these patients, and they were randomly assigned into consolidation group and control group. Relapse rate and Disease-free Survival were analyzed. Results 22 patients were assigned to consolidation group, and 22 patients as control group. The latest follow up examination was done in July 2005. Relapse rate was 45.5% in consolidation group, and 59.1% in control group (P=0.365). Mean relapse time in consolidation group was 25.3?9.3 months, and was 16.9?6.7 months in control group (P=0.019). Mean Disease-free Survival was 31.9?14.8 months in consolidation group, and was 22.7?12.9 months, in control group (P=0.033). Kaplan-Meier Survival Analysis showed no significant difference P=0.22. Conclusion Consolidation chemotherapy may postpone tumor relapse and prolong Disease-free survival in patients with clinical complete remission advanced epithelial ovarian carcinoma. While it hasn′t been proved but the results in present study did not prove that consolidation chemotherapy could lower relapse rate or elevate survival rate. Further study is needed to achieve better results.
